Steven AR Murphy: Urolithin A Shows Immune Rejuvenation and Mitochondrial Benefits in New Trial
Steven AR Murphy, Medical Director, Concierge Medical Associates, shared a post on LinkedIn:
”A Change in Urolithin A Dosing: What the Latest Human Data Means for Longevity Medicine
For years, Urolithin A has intrigued longevity researchers as a gut-derived molecule capable of activating mitophagy, the process of recycling worn-out mitochondria. In essence, it’s cellular housekeeping: clearing broken power plants so new ones can thrive.
Many of our patients take this for it’s Mitophagy benefit.
A newly published Nature Aging randomized, placebo-controlled trial has now brought real human evidence to the table. In just 28 days, healthy adults aged 45–70 who took 1,000 mg of Urolithin A daily showed clear biologic signs of immune rejuvenation and improved mitochondrial metabolism—with excellent safety.
Here’s what changed:
T cells looked and acted younger, with more naive-like CD8 cells and lower exhaustion markers.
Immune metabolism rewired, favoring fatty acid and amino acid oxidation (a signature of healthier, more resilient immunity).
Mitochondrial programs activated, including upregulation of PGC-1α, the master regulator of energy biogenesis.
From a clinical perspective, the data justify what we’re now implementing at Concierge Medical Associates.
While the study didn’t include a 500 mg arm, 1,000 mg is the only dose shown to move the biological levers of aging in humans.
If your goal is to enhance mitochondrial resilience, immune performance, and long-term vitality, this represents a practice-changing moment in longevity medicine and you can read my full analysis—including how I’m adjusting protocols—in the latest Longevity Insider with Dr. Murphy post here.”
Stay updated with Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia